Opportunity
Title: Cellink BIO X Advanced Multi-Material 3D Bioprinting System for Cancer Biology and Organoid Research
Response due
August 15, 2026
- Agency
- National Institutes of Health Olao
- Estimated value
- Not stated
THE LABORATORY INVESTIGATES MECHANISMS FO TUMORS INITIATIONS PROGRESSION AND THERAPEUTIC RESPONSE USING ADVANCED THREE DIMENSIONAL(3d) CULTURE SYSTEMS ORGANID MODELS AND ENGINEERED TISSUE MICRONMENTS . CURRENT RESEARCH FOCUESES ON UNDERSTANDING INTERACTIONS BETWEEN TUMORS CELLS AND THERI SURROUNDING STROMAL AND EXTRACULLULAR MATRIX ENVIRONMENTS THAT INFLUENCE CANCER DEVELOPMENT AND TREATMENT RESPONSE. EXISTING LABORATORY METHODS FOR GENERATING 3D TISSUEMODELS RELYON MANUAL PREPRATION TECHNIQUES THAT INTRODUCE VARIABILITY IN CONSTRUCT GEOMETRY, CELL DISTRUBUTION, AND EXTRACELLULAR MATRIX COMPOSITION. THESE LIMITATIONS REDUCE EXPERIMENTAL REPRODUCIBILITY AND RESTRICT THE COMPLEXITY OF TISSUE MODELS THAT CAN BE GENERATED. TO SUPPORT ONGOING NIH-FUNDED RESEARCH, THEMUTHUSWAMY LABORATORY REQUIRES A HIGH-PRECISION 3DE BIOPRINTING PLATFORM CAPABLE OF REPRODUCIBLY FABRICATING MULTICELLULAR TISSUE CONSTRUCTS USING A VARIETY OF BIOMARKS AND BIOMATERIALS. THE SYSTEM MUST INTEGRATE WITH EXISTING CELL CULTURE, MICROSCOPY, AND DOWNSTREAM MOLECULAR ANALYSIS WORKFLOWS WHILE ENABLING STANDARDIZED PRODUCTION OF PHYSIOLOGICALLY RELEVENT INVITRO MODELS.
Key dates
- Response due
- August 15, 2026
- Posted
- August 16, 2026
Who is this buyer
Organization
Buying history
- Records263 total
- Opportunities / awards10 / 20
- Value range$0 – $30,482,226
- ActiveJuly 15, 2026 – October 26, 2026
What they buy
- Clinical (251)
- Administrative (12)
Set-asides used
- No Set aside used (68)
- Small Business Set Aside - Total (14)
Who holds their work today
- EAGLE HEALTH, LLC1 win · $30,482,226 · last February 1, 2020
- LC INDUSTRIES INC1 win · $286,880 · last February 13, 2026
Also open from this buyer
- Clinical Research Support and Collaboration for NHGRI ProtocolsDue November 13, 2026 · Clinical
- NOI - 4D-Nucleofector Core Unit and X UnitDue November 5, 2026 · Clinical
- Reagents and consumables for Roche immunostainersDue October 28, 2026 · Clinical
- Combines Synopsis Solicitation- Automated SpatialDue November 5, 2026 · Clinical
View source document →
Source link on sam.gov.
Source record
- Buyer type
- Federal
- Jurisdiction
- Federal (US)
- Category
- Clinical
- Set-aside
- No Set aside used
- NAICS
- 541714
- PSC
- 6640